

## ERRATUM

### Smac mimetics: implications for enhancement of targeted therapies in leukemia

E Weisberg, A Ray, R Barrett, E Nelson, AL Christie, D Porter, C Straub, L Zawel, JF Daley, S Lazo-Kallanian, R Stone, I Galinsky, D Frank, AL Kung and JD Griffin

*Leukemia* (2011) **25**, 1221; doi:10.1038/leu.2011.83

**Correction to:** *Leukemia* (2010) **25**, 2100–2109; doi:10.1038/leu.2010.212

Owing to a typesetting error, the following sentence was incorrectly printed in the abstract section of the article:

‘The novel inhibitor of apoptosis (IAP), LCL161, was observed to potentiate the effects of tyrosine kinase inhibition against leukemic disease both in the absence and presence of a stromal protected environment. LCL161 enhanced the proapoptotic effects of nilotinib and PKC412, against leukemic disease *in vitro* and potentiated the activity of both kinase inhibitors against leukemic disease *in vivo*.’

The correct version is as follows:

‘The novel IAP inhibitor, LCL161, was observed to potentiate the effects of tyrosine kinase inhibition against leukemic disease both in the absence and presence of a stromal-protected environment. LCL161 enhanced the proapoptotic effects of nilotinib and PKC412, against leukemic disease *in vitro* and potentiated the activity of both kinase inhibitors against leukemic disease *in vivo*.’

The publishers would like to apologize for this error.